Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011749 | 0.88 | HTR2A (0.50) | HTR2AOPRM1 | |
| SCHEMBL5672694 | 0.87 | OPRM1 (0.61) | HTR2AOPRM1PNMT | |
| SCHEMBL13233728 | 0.87 | HTR2A (0.52) | HTR2AOPRM1PNMT | |
| SCHEMBL8942090 | 0.82 | HTR2A (0.45) | HTR2AOPRM1PNMT | |
| SCHEMBL24685408 | 0.80 | SLC6A3 (0.39) | HTR2A | |
| SCHEMBL12497300 | 0.80 | DRD2 (0.52) | HTR2A | |
| Hydrochloric Acid SCHEMBL5874086 | 0.79 | HTR2A (0.36) | HTR2A | |
| Hydrochloric Acid SCHEMBL5874154 | 0.79 | HTR2A (0.36) | HTR2A | |
| Hydrochloric Acid SCHEMBL5874176 | 0.77 | HTR2A (0.40) | HTR2AOPRM1 | |
| Hydrochloric Acid SCHEMBL5874182 | 0.77 | HTR2A (0.40) | HTR2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288414-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| CN-116806217-A | Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof | 拉帕塔疗法公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022167867-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-4840956-A | TREATING GRAM-POSITIVE BACTERIA | WARNER-LAMBERT COMPANY (US) | 1989-06-20 | — | — | US | disclosed |
| US-4735949-A | BROAD SPECTRA; GRAMPOSITIVE BACTERIA; BURN INJURIES | WARNER-LAMBERT COMPANY (US) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPP2CA, PPP3CA, PPP4C | HTR2A 1329/4885OPRM1 4347/4885PNMT 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.